— Know what they know.
Not Investment Advice

GMDA NASDAQ

Gamida Cell Ltd.
1W: +111.0% 1M: +116.6% 3M: -91.2% 1Y: -98.0% 3Y: -99.5% 5Y: -99.5%
$0.03
Last traded 2025-06-17 — delisted
NASDAQ · Healthcare · Biotechnology · $4.3M mcap · 120M float · 18.03% daily turnover

Cash Flow Trends

Operating Cash Flow
-$79M -12.3% ▼
Capital Expenditures
$1M +83.0% ▲
5Y CAGR: -8.1%
Free Cash Flow
-$80M -4.5% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$18M -306.5% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
— Operating Activities —
Net Income-$34M-$73M-$90M-$79M-$63M
Depreciation & Amort.$2M$2M$431K$440K$2M
Stock-Based Comp.$5M$3M$4M$5M$6M
Change in Working Capital$2M$7M$5M$4M-$11M
Other Non-Cash Items$2M$5M-$1M-$167K-$13M
Operating Cash Flow-$38M-$49M-$82M-$70M-$79M
— Investing Activities —
Capital Expenditures-$3M-$12M-$15M-$6M-$1M
Acquisitions (Net)-$7K$158K$5M$0$33K
Investment Purchases-$32M-$158K-$107M-$5M-$271K
Investment Sales$39M$14M$62M$45M$238K
Other Investing$7K-$158K-$5M$406K$271K
Investing Cash Flow$4M$2M-$61M$34M-$810K
— Financing Activities —
Net Debt Issuance$0$0$71M$23M-$2M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing-$1M$650K$626K$76K$45K
Financing Cash Flow$36M$132M$71M$45K$62M
Net Change in Cash$2M$85M-$71M$9M-$18M
Cash End of Period$42M$127M$56M$65M$47M
Free Cash Flow-$41M-$60M-$97M-$77M-$80M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms